Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Schett

Showing results (601-610 of 1,050) with videos related to

Pageof 105
Sort By:
Clinical and Experimental Rheumatology|January 13, 2017
Response of human rheumatoid arthritis osteoblasts and osteoclasts to adiponectinGrit Krumbholz, Susann Junker, Florian M P Meier, et al.
Rheumatology International|October 13, 2022
Digitally supported shared decision-making and treat-to-target in rheumatology: a qualitative study embedded in a multicenter randomized controlled trialFelix Muehlensiepen, Susann May, Katharina Hadaschik, et al.
Annals of the Rheumatic Diseases|August 24, 2012
Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1Katrin Palumbo-Zerr, Angelika Horn, Alfiya Distler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritisMarkus H Hoffmann, Jonatan Tuncel, Karl Skriner, et al.
ACR Open Rheumatology|July 26, 2020
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled TrialsPhilip J Mease, Dafna D Gladman, Juan J Gomez-Reino, et al.
Journal of Clinical Medicine|April 9, 2024
Patient Experiences and Challenges in the Management of Autoinflammatory Diseases-Data from the International FMF & AID Global Association SurveyJürgen Rech, Georg Schett, Abdurrahman Tufan, et al.
Arthritis and Rheumatism|May 30, 2009
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosusLuis E Muñoz, Christina Janko, Gerhard E Grossmayer, et al.
Cells|April 25, 2025
Increased Sensitivity to Ionizing Radiation in a Relevant Subset of Patients with Cancer and Systemic Lupus ErythematosusHannah Schenker, Lukas Kuhlmann, Dorothee Kaudewitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2013
NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseasesBettina Sehnert, Harald Burkhardt, Johannes T Wessels, et al.
Annals of the Rheumatic Diseases|August 18, 2017
Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosisJingang Huang, Christiane Maier, Yun Zhang, et al.
Pageof 105

Showing results (601-610 of 1,050) with videos related to

Sort By:
Pageof 105
Clinical and Experimental Rheumatology|January 13, 2017
Response of human rheumatoid arthritis osteoblasts and osteoclasts to adiponectinGrit Krumbholz, Susann Junker, Florian M P Meier, et al.
Rheumatology International|October 13, 2022
Digitally supported shared decision-making and treat-to-target in rheumatology: a qualitative study embedded in a multicenter randomized controlled trialFelix Muehlensiepen, Susann May, Katharina Hadaschik, et al.
Annals of the Rheumatic Diseases|August 24, 2012
Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1Katrin Palumbo-Zerr, Angelika Horn, Alfiya Distler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritisMarkus H Hoffmann, Jonatan Tuncel, Karl Skriner, et al.
ACR Open Rheumatology|July 26, 2020
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled TrialsPhilip J Mease, Dafna D Gladman, Juan J Gomez-Reino, et al.
Journal of Clinical Medicine|April 9, 2024
Patient Experiences and Challenges in the Management of Autoinflammatory Diseases-Data from the International FMF & AID Global Association SurveyJürgen Rech, Georg Schett, Abdurrahman Tufan, et al.
Arthritis and Rheumatism|May 30, 2009
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosusLuis E Muñoz, Christina Janko, Gerhard E Grossmayer, et al.
Cells|April 25, 2025
Increased Sensitivity to Ionizing Radiation in a Relevant Subset of Patients with Cancer and Systemic Lupus ErythematosusHannah Schenker, Lukas Kuhlmann, Dorothee Kaudewitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2013
NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseasesBettina Sehnert, Harald Burkhardt, Johannes T Wessels, et al.
Annals of the Rheumatic Diseases|August 18, 2017
Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosisJingang Huang, Christiane Maier, Yun Zhang, et al.
Pageof 105